GlassScriptPhysician profile
Lana Huling
NPI 1730712217
$3,322.66
in general payments reported to CMS, 2019-2025
20 companies · $886 in 2025
The $886 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $632 · 2022: $893 · 2023: $459 · 2024: $453 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,797.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,010.27 | 2021-2025 | Epclusa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $396.10 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $311.32 | 2022-2025 | Austedo Xr, Austedo Xr |
| Abbvie INC. | $243.44 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $204.40 | 2021-2025 | Ingrezza |
| Indivior INC. | $200.12 | 2021-2025 | Sublocade |
| Alkermes, INC. | $170.07 | 2021-2024 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $120.39 | 2023 | Quviviq |
| Alexion Pharmaceuticals, INC. | $113.71 | 2022 | |
| Agile Therapeutics, INC. | $111.37 | 2021 | |
| Janssen Pharmaceuticals, INC | $108.56 | 2024 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $61.55 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $60.12 | 2025 | Rexulti |
| Braeburn INC. | $46.91 | 2023-2025 | Brixadi |
| Axsome Therapeutics, INC. | $43.63 | 2024-2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $40.77 | 2021-2022 | |
| Organon LLC | $26.29 | 2023 | Nexplanon |
| Exact Sciences Corporation | $20.18 | 2025 | The Cologuard Plus Collection Kit |
| Orexo US, INC. | $18.05 | 2023 | Zubsolv |
| Vanda Pharmaceuticals INC. | $15.41 | 2025 | Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lana Huling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.